Prediabetes – 2009

Česká verzia

Authors: J. Rybka
Authors place of work: Diabetologické centrum Interní kliniky IPVZ Praha a Krajské nemocnice T. Bati, a. s., Zlín, přednosta doc. MUDr. Čestmír Číhalík, CSc.
Published in the journal: Vnitř Lék 2009; 55(9): 819-826
Category: 80th Birthday - prof. MUDr. Miloš Štejfa, DrSc., FESC

Summary

The concept of prediabetes has been discussed since the 1950’s. After 1980, WHO expert guidelines on the classification of diabetes according to its stages of development became common. These guidelines also included statistically significant risk groups with diabetes likely to develop in the future. The term Impaired Glucose Tolerance (IGT) was officially introduced by WHO in 1979, with an additional category referring to changes in glucose metabolism to be included later on – the Impaired Fasting Glucose – IFG. The term prediabetes mellitus began to be used again after 2000, and after 2003 diagnostic criteria to delimit diabetes and prediabetes came into use. Progressively, evidence was gathered on the involvement of hyperglycaemia and other metabolic abnormalities in patients with type 2 diabetes in creating conditions for the development of atherosclerosis. The last decade saw re-emerging publications dealing with the abnormalities of glucose metabolism, and subsequent statements from ADA, IDF and other organisations proposing the techniques of screening, diagnosis, monitoring and/or therapy of prediabetes. Recently, the American Diabetes Association clearly specifies the diagnosis of prediabetes, whereby prediabetes is defined within the scope of the diabetic disease. Prediabetes/diabetes reflect the continuum of the risk of microvascular and macrovascular outcomes. For these reasons, methods have been developed to delay the progression of prediabetes to diabetes. An ADA panel suggests that individuals with prediabetes should be enrolled in a program of intensive lifestyle intervention, with a specific group of patients at risk to be considered for therapy with metformin. Additional methods of prevention will be introduced into practice on the basis of new studies.

Key words:
stages of diabetes – type 2 diabetes mellitus – Impaired Glucose Tolerance – Impaired Fasting Glucose – screening – diagnosis – monitoring – prediabetes therapy – metformin

Zdroje

1. Alberti KG. American College of Endocrinology – Consensus Conference – Washington DC, 21–22 July 2008.

2. Alberti KG, Zimmet P, Shaw J. International Diabetes Federation: a consensus on type 2 diabetes prevention. Diabet Med 2007; 24: 451–463.

3. American Diabetes Association. Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2008; 31 (Suppl 1): S62–S67.

4. Burant CF. Medical Management of Type 2 Diabetes. 6th ed. Alexandria VA: American Diabetes Association 2008.

5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 (Suppl 1): S61–S67.

6. Kaufman FR. Medical Management of Type 1 Diabetes. 5th ed. Alexandria VA: American Diabetes Association 2008.

7. American Diabetes Association. Standards of medical care in diabetes – 2009. Diabetes Care 2009; 32 (Suppl 1): S13–S61.

8. Aroda VR, Ratner R. Approach to the patient with prediabetes. J Clin Endocrinol Metab 2008; 93: 3259–3265.

9. Bloomgarden ZT. American College of Endocrinology Pre-Diabetes Consensus Conference: part one. Diabetes Care 2008; 31: 2062–2069.

10. DECODE Study Group, European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardioascular and noncardiovascular diseases? Diabetes Care 2003; 26: 688–696.

11. DeFronzo R, Banerji MA, Bray G et al. ACTos NOW for the Prevention of Diabetes (ACT NOW) Study. Paper presented at the American Diabetes Association 68th Scientific Sessions. June 2008, at Moscone Convention Center, San Francisco, California.

12. Diabetes Prevention Program. Protocol for the Diabetes Prevention Program version 4.4–May 18, 2001. Available from: http://www.bsc.gwu.edu/dpp/3armprot.htmlvdoc,2001. Accessed 15 September 2008.

13. Diabetes Prevention Program. Repeat glucose testing to confirm glucose tolerance status: implications for diagnosing diabetes in high risk adults (Abstract). Diabetes 2006; 55 (Suppl 1): 894P.

14. DPP Research Group. Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 2003; 26: 977–980.

15. Dagenais GR, Gerstein HC, Holman R et al. DREAM Trial Investigators. Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial. Diabetes Care 2008; 31: 1007–1014.

16. Bosch J, Yusuf S, Gerstein HC et al. DREAM Trial Investigators. Effect of ramipril on the incidence of diabetes. Prev Cardiol 2007; 10: 48–51.

17. Genuth S, Alberti KG, Bennett P et al. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160–3167.

18. Foit R, Syllaba J et al. Diabetes mellitus. 2. přepracované vydání. Praha: Avicenum 1973.

19. Franz MJ, VanWormer JJ, Crain AL et al. Weight-loss outcomes: a systematic reviews and metaanalysis of weight-loss clinical trials with a minimum 1-year follow-up. J Am Diet Assoc 2007; 107: 1755–1767.

20. Gabir MM, Hanson RL, Dabelea D et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000; 23: 1108–1112.

21. Gerstein HC, Santaguida P, Raina P et al. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract 2007; 78: 305–312.

22. Gerstein HC. Point: If it is important to prevent type 2 diabetes, it is important to consider all proven therapies within a comprehensive approach. Diabetes Care 2007; 30: 432–434.

23. Haluzík M, Svačina Š. Metabolický syndrom a receptory PPAR. Praha: Grada Publishing 2005.

24. Holman RR, Paul SK, Bethel MA et al. 10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–1589.

25. Holman RR, Watkins PJ. UKPDS the first 30 years. UK: Wiley-Blackwell Publishing 2008.

26. Home PD, Jones NP, Pocock SJ et al. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med 2007; 24: F626–F634.

27. Chiasson JL, Josse RG, Gomis R et al. STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003; 290: 486–494.

28. Indian Health Services. 2006 IHS guidelines for care of adults with prediabetes and/or the metabolic syndrome in clinical settings. Available from: http: //www.ihs.gov/MedicalPrograms/Diabetes/resources/r_index.asp,2006. Accessed 27 August 2008.

29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352: 837–853.

30. Jackson WP. Prediabetes. Acta Diabetol Latina 1965; 2: 3.

31. Jahnke K et al. Der potentionelle Diabetes. 12. Symposium 1966. Die Pathogenese des Diabetes mellitus. Sborník Springer Verlag 1967.

32. Janssen PG, Gorter KJ, Stolk RP et al. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more averse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study. Prim Care Diabetes 2007; 1: 69–74.

33. Johnson SL, Tabaei BP, Herman WH. The efficacy and cost alternative strategies for systematic screening for type 2 diabetes in the U.S. population 45–74 years of age. Diabetes Care 2005; 28: 307–311.

34. Knowler WC, Barrett-Connor E, Fowler SE et al. Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.

35. Knowler WC, Hamman RF, Edelstein SL et al. Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 2005; 54: 1150–1156.

36. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanase trial in IGT males. Diabetes Res Clin Pract 2005; 67: 152–162.

37. Li G, Zhang P, Wang J et al. The long--term effect of lifestyle interventions to prevent diabetes in the China Da Qing Diabetes Prevention Study. A 20-year follow-up study. Lancet 2008; 371: 1783–1789.

38. Lindström J, Ilanne-Parikka P, Peltonen Met al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006; 368: 1673–1679.

39. Lindström J, Tuomilehto J. The diabetes risk score: a practical too to predict type 2 diabetes risk. Diabetes Care 2003; 26: 725–731.

40. Magliano D, Barr EL, Zimmet PZ et al. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. Diabetes Care 2008; 31: 267–272.

41. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA1c. Diabetes Care 2003; 26: 881–885.

42. Monnier L, Mas E, Ginet C et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681–1687.

43. Myint PK, Sinha S, Wareham NJ et al. Glycated hemoglobin and risk of stroke in people without known diabetes in the European Prospective Investigation into Cancer (EPIC) – Norfolk prospective population study: a threshold relationship? Stroke 2007; 38: 271–275.

44. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2009; 32: 193–203.

45. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006; 29: 1963–1972.

46. Nathan DM, Davidson MB, DeFronzo RA et al. American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007; 30: 753–759.

47. National Diabetes Surveillance System. Incidence of diabetes: crude and ageadjusted incidence of diagnosed diabetes per 1,000 population agend 18–79 years, United States, 1980–2006. Available from: http://www.cdc.gov/diabetes/statistics/incidence/fig2.htm, 2008. Accessed 18 August 2008.

48. Nichols GA, Hillier TA, Brown JB. Progression from newly acquired impaired fasting glucose to type 2 diabetes. Diabetes Care 2007; 30: 228–233.

49. Nijpels G, Boorsma W, Dekker JM et al. A study of the effects of acarbose on glucose metabolism in patients predisposed to developing diabetes: the Dutch Acarbose Intervention Study in Persons with Impaired Glucose Tolerance (DAISI). Diabetes Metab Res Rev 2008; 24: 611–616.

50. Rybka J et al. Diabetes mellitus. Zdravotnické aktuality, sv. 207. Praha: Avicenum 1985.

51. Salpeter SR, Buckley NS, Kahn JA et al. Meta-analysis: metformin treatment in persons at risk for diabetes mellitus. Am J Med 2008; 121: 149–157.

52. Saudek CD, Herman WH, Sacks DB et al. A new look at screening and diagnosing diabetes mellitus. J Clin Endocrinol Metab 2008; 93: 2447–2453.

53. Selvin E, Coresh J, Shahar E et al. Glycaemia (haemoglobin A1c) and incident ischaemic stroke: the Atherosclerosis Risk in Communities (ARIC) Study. Lancet Neurol 2005; 4: 821–826.

54. Söderberg S, Zimmet P, Tuomilehto J et al. High incidence of type 2 diabetes and increasing conversion rates from impaired fasting glucose and impaired glucose tolerance to diabetes in Mauritius. J Intern Med 2004; 256: 37–47.

55. Steinke R, Camerini R, Marble A et al. Elevated levels of serum ILA as measured with adipose tissue in early untreated diabetes and prediabetes. Metabolism 1961; 10: 707–711.

56. Stratton IM, Adler AI, Neil HAW et al. UK Prospective Diabetes Study Group. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–412.

57. Svačina Š. Prevence diabetu a jeho komplikací. Praha: Triton 2008.

58. Svačina Š. Prevence diabetu. Praha: Galén 2003.

59. Torgerson JS, Hauptman J, Boldrin MN et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 155–161.

60. Tuomilehto J, Lindström J, Eriksson JG et al. Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343–1350.

61. Twigg SM, Kamp MC, Davis TM et al. Australian Diabetes Society, Australian Diabetes Educators Association. Prediabetes: A position statement from the Australian Diabetes Society and Australian Diabetes Educators Association. Med J Aust 2007; 186: 461–465.

62. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2008; 148: 846–854.

63. U.S. Preventive Services Task Force. Screening for type 2 diabetes mellitus in adults: recommendations and rationale. Ann Inter Med 2003; 138: 212–214.

64. WHO/IDF consultation. Available from:http://www.who.int/diabetes/publica-tions/Definition%20and%20diagnosis%20diabetes_new.pdf,2006. Accessed 25 August 2008.

65. ADA Clinical Practice Recommendation 2009.